Body mass index and HER-2 overexpression in breast cancer patients over 50 years of age

T. Van Mieghem, K. Leunen, N. Pochet, B. De Moor, F. De Smet, F. Amant, P. Berteloot, D. Timmerman, I. Vanden Bempt, R. Drijkoningen, H. Wildiers, R. Paridaens, A. Smeets, Wouter R. Hendrickx, E. Van Limbergen, M. R. Christiaens, I. Vergote, P. Neven

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Purpose: In breast cancer, in vitro as well as in vivo experiments have shown an inverse relationship between HER-2 and steroid hormone receptors. It is unknown whether circulating estrogens affect HER-2 expression. We hypothesize that the postmenopausal body mass index (BMI) as a surrogate marker for bio-available estrogens, is inversely associated with HER-2 over-expression. Patients and methods: A total of 535 women over age 50 or with known postmenopausal status, with a unilateral, not previously treated, operable breast cancer were evaluated the evening prior to surgery for body weight, height, abdominal and hip circumference over a 3 years period. Waist-to-hip ratio (WHR) and BMI were calculated. HER-2, estrogen receptor and progesterone receptor staining was done by immunohistochemistry. All tumours with DAKO 2+ staining were submitted for HER-2 detection by FISH analysis. HER-2 was defined as positive if DAKO 3+ or FISH positive. We assessed the frequency of HER-2 positivity in each of 6 quantiles for all parameters of body composition and tested for a trend in HER-2 expression across the 6 quantiles. Furthermore, we investigated whether BMI contributed, together with other known predictors for HER-2, in a standard multivariate logistic regression model that predicts HER-2 over-expression. Results: There is a decrease in HER-2 over-expression per increasing quantile of BMI. In a multivariate model-including both steroid receptors-BMI remains an independent predictor for HER-2 over-expression. Conclusion: In women over age 50 or with known postmenopausal status with an operable breast cancer, there is an inverse association between BMI and HER-2 over-expression.

Original languageEnglish
Pages (from-to)127-133
Number of pages7
JournalBreast Cancer Research and Treatment
Volume106
Issue number1
DOIs
Publication statusPublished - 1 Nov 2007
Externally publishedYes

Fingerprint

Body Mass Index
Breast Neoplasms
Steroid Receptors
Estrogens
Logistic Models
Staining and Labeling
Body Height
Waist-Hip Ratio
Progesterone Receptors
Body Composition
Estrogen Receptors
Hip
Biomarkers
Immunohistochemistry
Body Weight
Hormones
Neoplasms

Keywords

  • Body mass index
  • Breast cancer
  • C-erb-B2
  • HER-2/neu
  • Obesity

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Van Mieghem, T., Leunen, K., Pochet, N., De Moor, B., De Smet, F., Amant, F., ... Neven, P. (2007). Body mass index and HER-2 overexpression in breast cancer patients over 50 years of age. Breast Cancer Research and Treatment, 106(1), 127-133. https://doi.org/10.1007/s10549-006-9474-7

Body mass index and HER-2 overexpression in breast cancer patients over 50 years of age. / Van Mieghem, T.; Leunen, K.; Pochet, N.; De Moor, B.; De Smet, F.; Amant, F.; Berteloot, P.; Timmerman, D.; Vanden Bempt, I.; Drijkoningen, R.; Wildiers, H.; Paridaens, R.; Smeets, A.; Hendrickx, Wouter R.; Van Limbergen, E.; Christiaens, M. R.; Vergote, I.; Neven, P.

In: Breast Cancer Research and Treatment, Vol. 106, No. 1, 01.11.2007, p. 127-133.

Research output: Contribution to journalArticle

Van Mieghem, T, Leunen, K, Pochet, N, De Moor, B, De Smet, F, Amant, F, Berteloot, P, Timmerman, D, Vanden Bempt, I, Drijkoningen, R, Wildiers, H, Paridaens, R, Smeets, A, Hendrickx, WR, Van Limbergen, E, Christiaens, MR, Vergote, I & Neven, P 2007, 'Body mass index and HER-2 overexpression in breast cancer patients over 50 years of age', Breast Cancer Research and Treatment, vol. 106, no. 1, pp. 127-133. https://doi.org/10.1007/s10549-006-9474-7
Van Mieghem, T. ; Leunen, K. ; Pochet, N. ; De Moor, B. ; De Smet, F. ; Amant, F. ; Berteloot, P. ; Timmerman, D. ; Vanden Bempt, I. ; Drijkoningen, R. ; Wildiers, H. ; Paridaens, R. ; Smeets, A. ; Hendrickx, Wouter R. ; Van Limbergen, E. ; Christiaens, M. R. ; Vergote, I. ; Neven, P. / Body mass index and HER-2 overexpression in breast cancer patients over 50 years of age. In: Breast Cancer Research and Treatment. 2007 ; Vol. 106, No. 1. pp. 127-133.
@article{e4e84145107a4e46ade7239151c30a59,
title = "Body mass index and HER-2 overexpression in breast cancer patients over 50 years of age",
abstract = "Purpose: In breast cancer, in vitro as well as in vivo experiments have shown an inverse relationship between HER-2 and steroid hormone receptors. It is unknown whether circulating estrogens affect HER-2 expression. We hypothesize that the postmenopausal body mass index (BMI) as a surrogate marker for bio-available estrogens, is inversely associated with HER-2 over-expression. Patients and methods: A total of 535 women over age 50 or with known postmenopausal status, with a unilateral, not previously treated, operable breast cancer were evaluated the evening prior to surgery for body weight, height, abdominal and hip circumference over a 3 years period. Waist-to-hip ratio (WHR) and BMI were calculated. HER-2, estrogen receptor and progesterone receptor staining was done by immunohistochemistry. All tumours with DAKO 2+ staining were submitted for HER-2 detection by FISH analysis. HER-2 was defined as positive if DAKO 3+ or FISH positive. We assessed the frequency of HER-2 positivity in each of 6 quantiles for all parameters of body composition and tested for a trend in HER-2 expression across the 6 quantiles. Furthermore, we investigated whether BMI contributed, together with other known predictors for HER-2, in a standard multivariate logistic regression model that predicts HER-2 over-expression. Results: There is a decrease in HER-2 over-expression per increasing quantile of BMI. In a multivariate model-including both steroid receptors-BMI remains an independent predictor for HER-2 over-expression. Conclusion: In women over age 50 or with known postmenopausal status with an operable breast cancer, there is an inverse association between BMI and HER-2 over-expression.",
keywords = "Body mass index, Breast cancer, C-erb-B2, HER-2/neu, Obesity",
author = "{Van Mieghem}, T. and K. Leunen and N. Pochet and {De Moor}, B. and {De Smet}, F. and F. Amant and P. Berteloot and D. Timmerman and {Vanden Bempt}, I. and R. Drijkoningen and H. Wildiers and R. Paridaens and A. Smeets and Hendrickx, {Wouter R.} and {Van Limbergen}, E. and Christiaens, {M. R.} and I. Vergote and P. Neven",
year = "2007",
month = "11",
day = "1",
doi = "10.1007/s10549-006-9474-7",
language = "English",
volume = "106",
pages = "127--133",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Body mass index and HER-2 overexpression in breast cancer patients over 50 years of age

AU - Van Mieghem, T.

AU - Leunen, K.

AU - Pochet, N.

AU - De Moor, B.

AU - De Smet, F.

AU - Amant, F.

AU - Berteloot, P.

AU - Timmerman, D.

AU - Vanden Bempt, I.

AU - Drijkoningen, R.

AU - Wildiers, H.

AU - Paridaens, R.

AU - Smeets, A.

AU - Hendrickx, Wouter R.

AU - Van Limbergen, E.

AU - Christiaens, M. R.

AU - Vergote, I.

AU - Neven, P.

PY - 2007/11/1

Y1 - 2007/11/1

N2 - Purpose: In breast cancer, in vitro as well as in vivo experiments have shown an inverse relationship between HER-2 and steroid hormone receptors. It is unknown whether circulating estrogens affect HER-2 expression. We hypothesize that the postmenopausal body mass index (BMI) as a surrogate marker for bio-available estrogens, is inversely associated with HER-2 over-expression. Patients and methods: A total of 535 women over age 50 or with known postmenopausal status, with a unilateral, not previously treated, operable breast cancer were evaluated the evening prior to surgery for body weight, height, abdominal and hip circumference over a 3 years period. Waist-to-hip ratio (WHR) and BMI were calculated. HER-2, estrogen receptor and progesterone receptor staining was done by immunohistochemistry. All tumours with DAKO 2+ staining were submitted for HER-2 detection by FISH analysis. HER-2 was defined as positive if DAKO 3+ or FISH positive. We assessed the frequency of HER-2 positivity in each of 6 quantiles for all parameters of body composition and tested for a trend in HER-2 expression across the 6 quantiles. Furthermore, we investigated whether BMI contributed, together with other known predictors for HER-2, in a standard multivariate logistic regression model that predicts HER-2 over-expression. Results: There is a decrease in HER-2 over-expression per increasing quantile of BMI. In a multivariate model-including both steroid receptors-BMI remains an independent predictor for HER-2 over-expression. Conclusion: In women over age 50 or with known postmenopausal status with an operable breast cancer, there is an inverse association between BMI and HER-2 over-expression.

AB - Purpose: In breast cancer, in vitro as well as in vivo experiments have shown an inverse relationship between HER-2 and steroid hormone receptors. It is unknown whether circulating estrogens affect HER-2 expression. We hypothesize that the postmenopausal body mass index (BMI) as a surrogate marker for bio-available estrogens, is inversely associated with HER-2 over-expression. Patients and methods: A total of 535 women over age 50 or with known postmenopausal status, with a unilateral, not previously treated, operable breast cancer were evaluated the evening prior to surgery for body weight, height, abdominal and hip circumference over a 3 years period. Waist-to-hip ratio (WHR) and BMI were calculated. HER-2, estrogen receptor and progesterone receptor staining was done by immunohistochemistry. All tumours with DAKO 2+ staining were submitted for HER-2 detection by FISH analysis. HER-2 was defined as positive if DAKO 3+ or FISH positive. We assessed the frequency of HER-2 positivity in each of 6 quantiles for all parameters of body composition and tested for a trend in HER-2 expression across the 6 quantiles. Furthermore, we investigated whether BMI contributed, together with other known predictors for HER-2, in a standard multivariate logistic regression model that predicts HER-2 over-expression. Results: There is a decrease in HER-2 over-expression per increasing quantile of BMI. In a multivariate model-including both steroid receptors-BMI remains an independent predictor for HER-2 over-expression. Conclusion: In women over age 50 or with known postmenopausal status with an operable breast cancer, there is an inverse association between BMI and HER-2 over-expression.

KW - Body mass index

KW - Breast cancer

KW - C-erb-B2

KW - HER-2/neu

KW - Obesity

UR - http://www.scopus.com/inward/record.url?scp=34848827968&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34848827968&partnerID=8YFLogxK

U2 - 10.1007/s10549-006-9474-7

DO - 10.1007/s10549-006-9474-7

M3 - Article

VL - 106

SP - 127

EP - 133

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 1

ER -